| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2004;78:1903-1909
© 2004 The Society of Thoracic Surgeons
a Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA and Division of Cardiothoracic Surgery, Department of Surgery, Birmingham Veterans Administration Hospital, Birmingham, Alabama; USA
b Department of Epidemiology, UAB School of Public Health, Birmingham, Alabama, USA
c Department of Clinical Pathology, UAB School of Public Health, Birmingham, Alabama, USA
d Department of Nuclear Medicine, UAB School of Public Health, Birmingham, Alabama, USA
e Department of Biostatistics, UAB School of Public Health, Birmingham, Alabama, USA
Accepted for publication June 2, 2004.
* Address reprint requests to Dr Cerfolio, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, 1900 University Blvd, THT 712, Birmingham, AL35294 (E-mail: robert.cerfolio{at}ccc.uab.edu).
BACKGROUND: Repeat positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) and chest computed tomography (CT) are used to assess the effectiveness of chemoradiotherapy in patients with non-small cell lung cancer (NSCLC); however, the change in the standardized uptake values (SUV) has not been correlated with the pathologic change of the primary tumor.
METHODS: This is a retrospective cohort study of a prospective database of 56 patients who had NSCLC, FDG-PET, and chest CT scans both before and after neoadjuvant therapy, followed by complete resection of their cancer. Maximum SUVs (maxSUV) and tumor size were measured, and the percentage of change was compared with the percentage of nonviable tumor cells. The primary objective was to measure the degree of correlation between these values.
RESULTS: The change in the maxSUV has a near linear relationship to the percent of nonviable tumor cells in the resected tumors. FDG-PET's maxSUV is better correlated to pathology than the change in size on CT scan (r2 = 0.75, r2 = 0.03, p < 0.001). When the maxSUV decreased by 80% or more, a complete pathologic response could be predicted with a sensitivity of 90%, specificity of 100%, and accuracy of 96%.
CONCLUSIONS: The change in maxSUV on FDG-PET scan after neoadjuvant therapy holds a near linear relationship with pathologic response. It is a more accurate predictor than the change of size on CT scan. When the maxSUV decreases by 80% or more it is likely that the patient is a complete responder irrespective of cell type, neoadjuvant treatment, or the final absolute maxSUV. These findings may help guide treatment strategies.
Related Article
Ann. Thorac. Surg. 2004 78: 1909.
This article has been cited by other articles:
|
|
 |
|
  C. Dooms, E. Verbeken, S. Stroobants, K. Nackaerts, P. De Leyn, and J. Vansteenkiste Prognostic Stratification of Stage IIIA-N2 Non-Small-Cell Lung Cancer After Induction Chemotherapy: A Model Based on the Combination of Morphometric-Pathologic Response in Mediastinal Nodes and Primary Tumor Response on Serial 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography J. Clin. Oncol., March 1, 2008; 26(7): 1128 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H.L. Goulart, J. W. Clark, H. H. Pien, T. G. Roberts, S. N. Finkelstein, and B. A. Chabner Trends in the Use and Role of Biomarkers in Phase I Oncology Trials Clin. Cancer Res., November 15, 2007; 13(22): 6719 - 6726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Cerfolio and A. S. Bryant When is it Best to Repeat a 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer Who Have Received Neoadjuvant Chemoradiotherapy? Ann. Thorac. Surg., October 1, 2007; 84(4): 1092 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-F. de Geus-Oei, H. F.M. van der Heijden, E. P. Visser, R. Hermsen, B. A. van Hoorn, J. N.H. Timmer-Bonte, A. T. Willemsen, J. Pruim, F. H.M. Corstens, P. F.M. Krabbe, et al. Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer J. Nucl. Med., October 1, 2007; 48(10): 1592 - 1598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-M. S. Kong, K. A. Frey, L. E. Quint, R. K. T. Haken, J. A. Hayman, M. Kessler, I. J. Chetty, D. Normolle, A. Eisbruch, and T. S. Lawrence A Pilot Study of [18F]Fluorodeoxyglucose Positron Emission Tomography Scans During and After Radiation-Based Therapy in Patients With Non Small-Cell Lung Cancer J. Clin. Oncol., July 20, 2007; 25(21): 3116 - 3123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cerfolio and A. S. Bryant Ratio of the Maximum Standardized Uptake Value on FDG-PET of the Mediastinal (N2) Lymph Nodes to the Primary Tumor May Be a Universal Predictor of Nodal Malignancy in Patients With Nonsmall-Cell Lung Cancer Ann. Thorac. Surg., May 1, 2007; 83(5): 1826 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT J. Nucl. Med., May 1, 2007; 48(5): 744 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kuehl, P. Veit, S. J. Rosenbaum, A. Bockisch, and G. Antoch Can PET/CT Replace Separate Diagnostic CT for Cancer Imaging? Optimizing CT Protocols for Imaging Cancers of the Chest and Abdomen J. Nucl. Med., January 1, 2007; 48(1_suppl): 45S - 57S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Cerfolio, A. S. Bryant, E. Scott, M. Sharma, F. Robert, S. A. Spencer, and R. I. Garver Women With Pathologic Stage I, II, and III Non-small Cell Lung Cancer Have Better Survival Than Men Chest, December 1, 2006; 130(6): 1796 - 1802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Lobrano Partnerships in Oncology and Radiology: The Role of Radiology in the Detection, Staging, and Follow-up of Lung Cancer Oncologist, July 1, 2006; 11(7): 774 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Cerfolio, A. S. Bryant, and B. Ojha Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1229 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, R. Pink, W. Eberhardt, G. Stamatis, T. Gauler, G. Antoch, et al. Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in Non-Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy Clin. Cancer Res., January 1, 2006; 12(1): 97 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Barlesi, C. Doddoli, J.-P. Torre, R. Giudicelli, P. Fuentes, P. Thomas, and P. Astoul Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 629 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Milleron, V. Westeel, E. Quoix, D. Moro-Sibilot, D. Braun, B. Lebeau, A. Depierre, and for the French Thoracic Cooperative Group Complete Response Following Preoperative Chemotherapy for Resectable Non-Small Cell Lung Cancer: Accuracy of Clinical Assessment Using the French Trial Database Chest, September 1, 2005; 128(3): 1442 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cerfolio, A. S. Bryant, B. Ohja, and A. A. Bartolucci The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 151 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cerfolio, A. S. Bryant, B. Ohja, A. A. Bartolucci, and M. A. Eloubeidi The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy J. Thorac. Cardiovasc. Surg., June 1, 2005; 129(6): 1232 - 1241. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
